Gentian Diagnostics ASA (OB: GENT)
Health Care · Health Care Equipment & Supplies · NO
Nkr38.50
-1.28% today · -29.6% 1Y
Gentian Diagnostics ASA (OB: GENT) operates in the Health Care Equipment & Supplies industry within the Health Care sector. The company is valued at $63.02M and employs 64 people.
Over the last twelve months the share price has lost 29.6%, trading between 33.50 and 60.00.
Tweenvest scores Gentian Diagnostics ASA across four factors: quality 78/100, value 56/100, growth 88/100, dividend 25/100. Its strongest factor is growth.
GENT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $63.02M
- Revenue (TTM)
- $18.38M
- P/E
- —
- EPS
- -0.54
- Dividend yield
- 1.54%
- Beta (5Y)
- 0.52
- 52-week high
- Nkr60.00
- 52-week low
- Nkr33.50
- Avg volume (3M)
- —
- Shares outstanding
- 15.46M
- Employees
- 64
- Next earnings
- —
About Gentian Diagnostics ASA
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
- ISIN
- NO0010748866
- Founded
- 2001
- Listed since
- Dec 14, 2016
- Exchange
- Oslo Bors
- Currency
- NOK
Other Health Care Equipment & Supplies companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Namwiwat Medical Corporation Public Company LimitedSET: NAM | $65.51M | ฿3.14 | -0.63% |
| RecensMedical, Inc.KOSDAQ: A394420 | $63.90M | ₩7,810.00 | -10.84% |
| Medicalgorithmics S.A.WSE: MDG | $63.51M | zł24.80 | -0.80% |
| OSTEONIC Co., Ltd.KOSDAQ: A226400 | $63.42M | ₩4,250.00 | +2.04% |
| Creo Medical Group PLCAIM: CREO | $62.28M | £0.11 | 0.00% |
| Abingdon Health PlcAIM: ABDX | $61.89M | £0.11 | 0.00% |
| Austco Healthcare LimitedASX: AHC | $61.46M | AU$0.24 | -6.00% |
| OK Biotech Co., Ltd.TWSE: 4155 | $61.26M | NT$14.20 | -4.38% |
Figures last refreshed Oct 11, 2026.